The ‘Kidney Cancer UK Accord: Consensus Statement’ seeks to establish a common pathway for all patients across England and Wales.
Kidney cancer is the 7th most common cancer in the UK. Of the six cancers that are more common than kidney cancer, only lung cancer is more difficult to treat successfully.
As such, kidney cancer is a significant cancer in an important organ within the body. However, there is a low level of awareness of kidney cancer and the symptoms that patients may present with. Also, although there are pockets of excellence, there is significantly less research and funding for research into this cancer compared to other cancers – particularly in the area of non-metastatic disease. These factors are reflected in the lack of an agreed quality framework around key aspects of the patient pathway.
This Consensus Statement aims to develop the key elements of good quality in kidney cancer care across England and Wales. In due course this will be supported by a set of Quality Performance Indicators. The aim is the development of an overarching NICE Clinical Guideline for kidney cancer, similar to the other existing NICE guidelines for many comparable conditions
A useful companion to our document is the paper ‘Overcoming Equality: Achieving Better Outcomes for Kidney Cancer’ published late 2019 by pharmaceutical company Bristol-Myers Squibb and endorsed by Kidney Cancer UK. You can
download and read a copy of this report by clicking the image to the right.